Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389904 | 1.00 | TGFBR1 (0.41) | TGFBR1MAPK14CDK4CDK2AKT1 | |
| SCHEMBL25084975 | 0.88 | TGFBR1 (0.42) | TGFBR1MAPK14AKT1AKT2 | |
| SCHEMBL30156165 | 0.87 | TGFBR1 (0.39) | TGFBR1MAPK14CDK4CDK2AKT1 | |
| SCHEMBL25084498 | 0.87 | TGFBR1 (0.39) | TGFBR1MAPK14CDK4CDK2AKT1 | |
| SCHEMBL29796459 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14CDK2AKT1AKT2 | |
| SCHEMBL23389972 | 0.86 | TGFBR1 (0.42) | TGFBR1MAPK14CDK2AKT1AKT2 | |
| SCHEMBL29796664 | 0.82 | MAPT (0.39) | TGFBR1CDK4CDK2 | |
| SCHEMBL23389872 | 0.82 | MAPT (0.39) | TGFBR1CDK4CDK2 | |
| SCHEMBL25084925 | 0.81 | TGFBR1 (0.39) | TGFBR1CDK4CDK2FGFR1FGFR2 | |
| SCHEMBL30156039 | 0.81 | TGFBR1 (0.39) | TGFBR1CDK4CDK2FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4061809-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885MAPK14 1504/4885CDK4 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.